Immunovant's FcRn Strategy Gains Momentum: Analysts View ADHERE Study as De-Risking Factor for CIDP Clinical Development
Portfolio Pulse from Vandana Singh
Immunovant Inc's (NASDAQ:IMVT) FcRn strategy gains momentum as analysts view the ADHERE study as a de-risking factor for CIDP clinical development. The study was conducted by Argenx SE (NASDAQ:ARGX). Stifel has increased the price target for Immunovant from $28 to $34, and HC Wainwright has revised its price target from $27 to $29. The positive ADHERE data supports the autoantibody hypothesis in CIDP, suggesting that most CIDP patients could benefit from an FcRn inhibitor.
July 18, 2023 | 6:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Argenx SE's ADHERE study has met its primary endpoint, leading to increased confidence in Immunovant's similar FcRn strategy. This could potentially have a positive impact on Argenx's stock.
The success of Argenx's ADHERE study has led to increased confidence in Immunovant's similar FcRn strategy. This could potentially have a positive impact on Argenx's stock in the short term.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
Immunovant's FcRn strategy is seen as gaining momentum following positive results from the ADHERE study. Analysts have increased the price target for the company, suggesting confidence in its future performance.
The positive results from the ADHERE study, which supports the autoantibody hypothesis in CIDP, have led analysts to increase the price target for Immunovant. This suggests a positive short-term impact on the company's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100